‘s-Hertogenbosch, The Netherlands, January 15 /PRNewswire/ -- PamGene International BV, a private Dutch company providing pioneering Life Science products for disease research and drug discovery, today announced the signing of a co-marketing agreement with Life Sciences leader, Invitrogen Corporation a provider of essential life science technologies for research, production and diagnostics.
Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen’s Nuclear Hormone Receptor proteins and Lanthascreen(R) assay technology with PamGene’s portfolio of microarray-based Nuclear Hormone Receptor screening tools; specifically its PamChip(R) applications and PamStation(R) instrumentation. This creates a complete offering for compound screening in drug discovery in the areas of cancer, diabetes and heart disease. The current market for nuclear receptor targeted drugs is estimated to be 10-15% of the $400 billion global pharmaceutical market.
About PamGene
PamGene’s novel multi-protein interaction technology delivers innovative solutions for cancer biomarker discovery, drug development and disease diagnosis. The company’s Nuclear Hormone Receptor and Kinase research products are sold worldwide to pharma, biotech and academic customers. As well as preclinical applications, PamGene’s products are also used for development of new drug activity-based companion diagnostics, aimed to help doctors make a more personalised choice of cancer therapy. Such a scenario would benefit patients, pharmaceutical companies and health insurance providers alike.
About Invitrogen
Invitrogen Corporation provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen’s own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen’s products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company is celebrating 20 years of accelerating scientific discovery. Invitrogen globally employs approximately 4,700 scientists and other professionals and had revenues of more than $1.15 billion in 2006. For more information, visit http://www.invitrogen.com.
http://www.pamgene.com
CONTACT: Further information: PamGene International BV, Morven Brodie,
Communications Manager, PO Box 1345, 5200 BJ ‘s-Hertogenbosch, The
Netherlands, Tel.: +31(0)73-6158-967, mbrodie@pamgene.com
